Literature DB >> 1749203

Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina.

S Wieshammer1, M Hetzel, U Barnikel, M Höher, H Seibold, M Kochs, V Hombach.   

Abstract

The effects of atenolol, nifedipine, and their combination on gas exchange and exercise tolerance were studied in 27 patients with effort angina and normal global ventricular function in an open-label and randomized cross-over trial. Symptom-limited semi-supine exercise tests using a ramp protocol (20 W/min) with simultaneous breath-by-breath analysis of gas exchange were carried out after a 4-day wash-out period and after consecutive 2-week treatment periods with atenolol (50 mg b.i.d.), slow-release nifedipine (20 mg b.i.d.), and their combination (b.i.d.). Exercise tolerance was not significantly higher with atenolol than with nifedipine [118(24) vs 113(23) W]. Combination therapy [120(23) W] was more effective than monotherapy with nifedipine (p less than 0.05) but produced no further increase in exercise tolerance over atenolol monotherapy. Maximum oxygen uptake was not significantly different among the treatments. In the range of light to moderate exercise, the slope of the VO2-workload regression line expressed as ml.min-1.W-1 was lower with atenolol than with nifedipine [8.64(1.59) vs 10.28(1.74), p less than 0.005] and intermediate with combination therapy [9.99(1.83)]. The intercept on the VO2 axis was higher with atenolol than with nifedipine [366(111) vs 299(113) ml.min-1, p less than 0.05]. A similar pattern of results was seen when the drug effects on the slope of the VCO2-workload relation were analyzed. VE was higher with nifedipine than with atenolol at all points of the regression analysis [greater than 30 W].(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749203     DOI: 10.1007/bf01649425

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  31 in total

1.  Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function.

Authors:  I N Findlay; K MacLeod; M Ford; G Gillen; A T Elliott; H J Dargie
Journal:  Br Heart J       Date:  1986-03

2.  The oxygen cost of breathing during vigorous exercise.

Authors:  R J Shephard
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1966-10

3.  Atenolol and/or nifedipine in effort angina: which is the treatment of choice for exercise coronary protection?

Authors:  M Romano; T Di Maro; G Carella; M R Cotecchia; M R Caiazzo; E de Arcangelis; M Chiariello; M Condorelli
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1988-09

4.  Treatment of angina pectoris with nifedipine: a double blind comparison of nifedipine and slow-release nifedipine alone and in combination with atenolol.

Authors:  T Crake; A A Quyyumi; C Wright; L Mockus; K M Fox
Journal:  Br Heart J       Date:  1987-12

5.  The anaerobic threshold in chronic heart failure. Relation to blood lactate, ventilatory basis, reproducibility, and response to exercise training.

Authors:  M J Sullivan; F R Cobb
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

6.  Long-term reproducibility of respiratory gas exchange measurements during exercise in patients with stable cardiac failure.

Authors:  J S Janicki; S Gupta; S T Ferris; P A McElroy
Journal:  Chest       Date:  1990-01       Impact factor: 9.410

7.  Atenolol with and without nifedipine in the treatment of angina pectoris. Preliminary report.

Authors:  M Sandberg; R A Foale
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  [Anti-angina effectiveness of the calcium antagonist nifedipine in relation to coronary involvement].

Authors:  W Schulz; S Jost; M Kaltenbach; G Kober
Journal:  Z Kardiol       Date:  1983-11

9.  Effects of nifedipine on systemic and regional oxygen transport and metabolism at rest and during exercise.

Authors:  C Y Choong; G S Roubin; W F Shen; P J Harris; D T Kelly
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

10.  Cardiopulmonary exercise testing for evaluation of chronic cardiac failure.

Authors:  K T Weber; J S Janicki
Journal:  Am J Cardiol       Date:  1985-01-11       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.